Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 in Generalized Anxiety Disorder
NCT05729373Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of ulotaront in generalized anxiety disorder (GAD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Mar 2023; status: completed.
02
Drugs
ulotaront
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT05729373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05729373.